Segment 1 — The Cold Open

Segment 2 — The Good Intention

Diclofenac had been developed in the 1970s as a non-steroidal anti-inflammatory for human arthritis and post-operative pain. When its patent lapsed in the early 1990s, Indian pharmaceutical firms produced inexpensive versions that farmers could afford. Before this shift, livestock owners had few practical options for relieving the pain and inflammation that reduced milk yields and draft power in working animals. The drug therefore appeared to be a straightforward welfare and productivity gain for millions of smallholders who previously watched cattle suffer without treatment. No one at the time tested the compound on the obligate scavengers that cleaned the countryside of dead livestock. Farmers in the Gangetic plain and Rajasthan, where cattle densities were highest, saw immediate improvements in animal mobility after a single low-cost injection; the same dose that eased joint swelling in a bullock also kept the animal productive for another season of plowing or hauling. Because diclofenac was already approved for human use, regulators treated its extension to livestock as a minor administrative step rather than a new environmental release. The economic logic was simple arithmetic: one vial treated several animals at a fraction of the price of imported alternatives, and milk output or field work could resume within days instead of weeks. In the absence of any published data on avian kidney physiology, the decision carried no visible downside for the people who made or administered it.

Segment 3 — The Implementation

By the mid-1990s veterinary use of diclofenac had spread rapidly through the cattle belt of northern and western India. Roadside pharmacies and livestock markets stocked the human formulation in vials labeled for cattle, and farmers injected animals shortly before slaughter or natural death. Early surveys by the Bombay Natural History Society recorded no obvious change in carcass availability; vultures still arrived in large numbers at known feeding sites. A few ornithologists noted occasional dead birds with white urate deposits around the vent, but these incidents were treated as isolated disease events rather than a systemic threat. The scale of adoption can be traced in pharmacy sales records: once the molecule entered the generic market, annual production volumes rose from laboratory quantities to hundreds of tonnes, enough to dose millions of cattle each year across states where open grazing was the norm. Because the human and veterinary supply chains were not yet separated by regulation, the same blister packs moved from urban hospitals to rural veterinary shops with minimal friction. Early monitoring efforts focused on whether the drug reduced clinical signs in livestock; no parallel program tracked residue levels in the carcasses those livestock left behind. The first systematic necropsies that later linked the drug to vulture mortality were still years away, so the absence of reported problems was taken as evidence of safety.

Segment 4 — The Unintended Consequences

The causal chain began when a treated animal died and its carcass retained enough diclofenac residue to kill any vulture that fed on it. In 2004, J. Lindsay Oaks and colleagues published in Nature the experimental proof that oral doses matching those found in treated livestock produced the visceral gout and kidney failure already seen in field carcasses. By 2007 the oriental white-backed vulture had declined to 0.1 percent of its early-1990s numbers, according to repeated road-transect surveys reported in PLOS One. With the primary scavengers gone, carcasses persisted for days at village dumps and urban waste sites. Feral dog populations rose sharply, increasing the incidence of dog bites and rabies. At the same time, surface water near carcass dumps showed elevated bacterial loads. Using the natural experiment of districts that historically differed in vulture habitat suitability, economists Eyal Frank and Anant Sudarshan estimated in the American Economic Review that all-cause human mortality rose 4.7 percent in high-suitability districts between 2000 and 2005—an average of more than 100,000 additional deaths per year. The arithmetic of exposure is straightforward once the residue data are examined: a single treated buffalo could contain several lethal doses for a vulture, and because Gyps species feed in groups of dozens, one contaminated carcass removed multiple breeding adults in a single afternoon. Without those adults returning to nests, recruitment collapsed; the 97 percent drop recorded between the early 1990s and 2007 left too few birds to process the daily volume of livestock mortality across the subcontinent. The resulting sanitation gap operated through two measurable pathways. First, feral dog numbers increased because an abundant, previously contested food source was now uncontested; each additional dog raised the probability of a human bite, and India already accounted for roughly a third of global rabies deaths. Second, uneaten carcasses leached pathogens into shallow aquifers and streams used for washing and irrigation, an effect concentrated in the same districts that had once supported the densest vulture colonies. The 4.7 percent mortality increase measured by Frank and Sudarshan therefore reflects both direct zoonotic risk and the broader degradation of local water quality once the keystone scavenger was removed.

Segment 5 — The Aftermath

India banned veterinary diclofenac in 2006 and strengthened the prohibition in 2008. Follow-up carcass surveys published in PLOS One showed the prevalence of diclofenac-contaminated livestock fell from roughly 10.8 percent before the ban to 6.5 percent several years later, slowing but not stopping vulture declines. Necropsies of vultures found dead between 2008 and 2012, reported in Oryx, revealed that some birds still carried diclofenac while others showed nimesulide residues associated with the same gout pathology. Human-formulation diclofenac continues to be diverted into veterinary channels, and populations of the three Gyps species remain at a few percent of pre-1990s levels with only modest signs of recovery. The persistence of the drug after the formal ban illustrates the difficulty of separating two parallel supply chains that share the same molecule and the same manufacturing plants. Even after the 2008 tightening, which required colored dyes and larger vial sizes for human formulations, enforcement relied on state-level pharmacy inspections that could not monitor every rural transaction. Meanwhile, alternative NSAIDs such as nimesulide entered the veterinary market without the same level of pre-release testing against vulture kidney tissue, reproducing the original oversight at a smaller scale.

Segment 6 — The Lesson

When regulators approved diclofenac for livestock they evaluated only the intended patient species and the immediate economic return to farmers. The same narrow approval process rewarded any low-cost drug that cleared livestock quickly, without requiring tests on the scavengers whose removal would later impose sanitation costs measured in tens of thousands of human lives. A second principle is that once a compound enters widespread agricultural use, even a later ban on the veterinary formulation can be undermined by leakage from the parallel human supply chain that regulators continue to authorize. The episode therefore asks whether any new veterinary pharmaceutical should be required to demonstrate safety for the entire local scavenger community before it receives marketing approval. That requirement would shift the burden of proof from post-release mortality counts to pre-release feeding trials, exactly the step that was omitted when diclofenac moved from human medicine into Indian cattle herds in 1994.

Sources

• aeaweb.org — The Social Costs of Keystone Species Collapse: Evidence from the Decline of Vultures in India
• cambridge.org — Continuing mortality of vultures in India associated with illegal veterinary use of diclofenac and a potential threat from nimesulide
• journals.plos.org — The Population Decline of Gyps Vultures in India and Nepal Has Slowed since Veterinary Use of Diclofenac was Banned
• journals.plos.org — Effectiveness of Action in India to Reduce Exposure of Gyps Vultures to the Toxic Veterinary Drug Diclofenac
• pure.psu.edu — Diclofenac poisoning is widespread in declining vulture populations across the Indian subcontinent
• nature.com — Diclofenac residues as the cause of vulture population decline in Pakistan

💬 Reply to this email — Patrick reads every one.

Share: X · LinkedIn · WhatsApp

Forwarded this email? Subscribe here — it's free.